Krystal Biotech (NASDAQ:KRYS) Sets New 12-Month Low - Should You Sell?

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $122.80 and last traded at $126.06, with a volume of 298645 shares traded. The stock had previously closed at $125.29.

Analyst Upgrades and Downgrades

Several brokerages have commented on KRYS. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Citigroup lowered their price objective on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday, May 16th. Finally, Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has an average rating of "Buy" and an average price target of $211.13.

Krystal Biotech Stock Down 2.4%

The company's fifty day moving average price is $157.54 and its two-hundred day moving average price is $165.70. The company has a market cap of $3.56 billion, a price-to-earnings ratio of 41.26 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently made changes to their positions in the company. FMR LLC grew its holdings in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after acquiring an additional 21,133 shares during the period. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after purchasing an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Krystal Biotech by 0.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after purchasing an additional 6,600 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after purchasing an additional 365,304 shares during the period. Finally, Hood River Capital Management LLC grew its stake in shares of Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after purchasing an additional 10,622 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).